Overview
Drug development has long been measured in molecules, mechanisms, and milestones. However, behind the scenes of a medication reaching patients are thousands of decisions made over more than a decade, by people most patients will never meet.
And in the first episode of Pharma Pulse, we start mapping that story end-to-end. Ananya Shukla, Market Access Strategist, sits down with Dr. Tony Williams, Country Manager (USA) at Ingenious e-Brain, to break down the entire value chain in plain language, then put widely held myths about the pharmaceutical industry to the test.
What’s This Episode All About?
Episode 01 sets the foundation for the entire Pharma Pulse podcast series. Tony walks through the pharma value chain as a relay race, consisting of discovery; pre-clinical testing; clinical development; regulatory review; market access; and post-market surveillance. He identifies specifically where data resides within each leg of the race.
The conversation covers:
- The full pharma value chain, explained through a simple relay race analogy
- Where data and technology actually sit inside drug development, at every single stage
- A live myth-busting round on common beliefs about the pharma industry
- Why regulatory approval is “crossing the halfway line; not the finish line”
- What’s currently broken in the pharma value chain and needs to be changed
- How Ingenious e-Brain can support pharma companies in filling critical gaps across the value chain
Why Are We Telling This Story?
We sit across the table from pharma companies, navigating exactly the value chain this episode maps. Three things shaped how we built this conversation, and this season:
- Bridging the Knowledge Gap Across Functions: Commercial teams, clinical teams, data scientists, and medical affairs each understand their own slice of the chain deeply. Very few people inside an organization understand the whole thing. This series is built to close that gap.
- Placing Data Where it Actually Belongs: Across discovery, regulatory submission, and payer negotiation, data does not just support the process. Increasingly, data is the process. We wanted that point made early, and made clearly.
The pharma value chain moves on its own clock, often more than a decade per medicine. The real advantage belongs to the teams who understand every leg of that race, not just their own.
Where Does This Podcast Series Go From Here?
- Episode 2, Drug Discovery and Pre-Clinical Research: How AI is now screening billions of compounds in silico, work that used to take decades inside a wet lab.
- Episode 3, Clinical Trials, Phases One Through Three: A full walkthrough of every trial phase, including a patient’s own account of what enrolling actually feels like.
- Episode 4, Regulatory and Submission Process: A conversation with someone who once reviewed submissions from inside the FDA, before moving into industry.
- Episode 5, Medical Affairs: How pharma educates physicians and the wider healthcare community once a drug clears regulatory review.
- Episode 6, Market Access: The payer negotiations and pricing conversations that decide whether a drug ever reaches a formulary.
- Episode 7, Client Success Stories: A full anthology of real engagements from the field.
- Episode 8, Future of Pharma: Closing out the season with a discussion of where the industry goes next.
Speakers
Tony Williams
Consultant
Ananya Shukla
Client Relationship Executive - Healthcare
